公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)! YZ剂描述: 产品名称:Cevipabulin (TTI-237) 产品别名:西维布林 英文别名:TTI237;D06576 靶点:Microtubule/Tubulin CAS:849550-05-6 纯度:>98% 外观:见爱必信官网 保存方法:store at -20℃ for one year(Powder); in DMSO or others solvent store at 2-4℃ for two weeks, at -20℃ for six months. 描述: Cevipabulin (TTI-237), an antimicrotubule agent, is a small synthetic molecule of triazolopyrimidine derivative with potential antitumor activity. With a novel mechanism of action distinct from the action of other vinca alkaloid compounds, TTI-237 specifically binds to tubulin at the vinca site, and promotes the polymerization of tubulin into microtubules. 溶解性:DMSO: 10 mg/mL 体外研究: Cevipabulin (0-50 nM, 72 hours) shows good activity (between 18 and 40 nM IC50 values) on cell lines from ovarian, breast, prostate, and cervical tumors. Flow cytometry experiments reveal that, Cevipabulin (TTI-237) at low concentrations (20-40 nM) produces sub-G1 nuclei and, at concentrations above 50 nM, it causes a strong G2-M block. Cell Cytotoxicity Assay Cell Line: | Human cancer cell lines (SK-OV-3, MDA-MB-435, MDA-MB-468, LnCaP, and Hela cells). | Concentration: | 0-50 nM | Incubation Time: | 72 hours | Result: | The IC50 values are 24±8 nM, 21±4 nM, 18±6 nM, 22±7 nM and 40 nM in SK-OV-3, MDA-MB-435, MDA-MB-468, LnCaP and Hela cells. |
体内研究: Cevipabulin (TTI-2370)( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles, in mice) is active by i.v. and p.o. administration against human tumor xenografts, showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg. Animal Model: | Athymic nu/nu female mice implanted s.c. in the flank with 1×107 LoVo human colon adenocarcinoma cells | Dosage: | 5, 10, 15, and 20 mg/kg | Administration: | I.V. injection every 4 days for 4 cycles. | Result: | The compound showed dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg. |
产品信息订购: 产品货号 | 产品名称 | 规格 | 价格 | 大包装及货期 | abs811179 | Cevipabulin (TTI-237) | 50mg | 8160 | 立即咨询 | 产品更多信息请进入爱必信网站咨询 |